Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,505.75 -705.91 (-1.10%) CMC Crypto 200
1,322.42 -74.12 (-5.31%)
Synaptogenix, Inc. (SNPX)
| Previous close | 4.4100 |
| Open | 4.5237 |
| Bid | 4.1800 x 100 |
| Ask | 4.4600 x 100 |
| Day's range | 4.4300 - 4.5237 |
| 52-week range | 3.5250 - 47.0000 |
| Volume | |
| Avg. volume | 50,339 |
| Market cap | 4.808M |
| Beta (5Y monthly) | 1.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -29.5000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireSynaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for continued listing on The Nasdaq Capital Market.
PR NewswireSynaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based t
PR NewswireSynaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing
Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares. The reverse stock split will become effective at 5:00 p.m. Eastern Standard Time on Thursday, April 4, 2024. SNPX common stock will continue to be traded on The Nasdaq Capital Market under
